Want to see HK:2627 full AI Analyst Report?
Ab&B Bio-Tech CO., LTD. JS Class H (2627) Ratios
Ab&B Bio-Tech CO., LTD. JS Class H Ratios
HK:2627's free cash flow for Q2 2025 was $-25.00M. For the 2025 fiscal year, HK:2627's free cash flow was decreased by $-14.93M and operating cash flow was $-10.07M. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 23 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 0.55 | 0.40 |
| Quick Ratio | 0.48 | 0.32 |
| Cash Ratio | 0.15 | 0.09 |
| Solvency Ratio | -0.14 | -0.50 |
| Operating Cash Flow Ratio | -0.22 | -0.58 |
| Short-Term Operating Cash Flow Coverage | -0.57 | -1.40 |
| Net Current Asset Value | $ -970.72M | $ -543.23M |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.53 | 0.38 |
| Debt-to-Equity Ratio | 5.86 | 1.16 |
| Debt-to-Capital Ratio | 0.85 | 0.54 |
| Long-Term Debt-to-Capital Ratio | 0.76 | 0.29 |
| Financial Leverage Ratio | 11.00 | 3.08 |
| Debt Service Coverage Ratio | -0.50 | -1.65 |
| Interest Coverage Ratio | -12.93 | -63.94 |
| Debt to Market Cap | 0.07 | 0.03 |
| Interest Debt Per Share | 2.23 | 1.09 |
| Net Debt to EBITDA | -4.00 | -1.02 |
| Profitability Margins | ||
| Gross Profit Margin | 58.34% | -39.00% |
| EBIT Margin | -92.83% | -801.51% |
| EBITDA Margin | -70.03% | -709.55% |
| Operating Profit Margin | -88.24% | -809.99% |
| Pretax Profit Margin | -99.65% | -814.18% |
| Net Profit Margin | -99.65% | -814.18% |
| Continuous Operations Profit Margin | -99.65% | -814.18% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | 112.93% | 100.52% |
| Return on Assets (ROA) | -16.04% | -37.93% |
| Return on Equity (ROE) | -176.49% | -116.92% |
| Return on Capital Employed (ROCE) | -32.53% | -71.55% |
| Return on Invested Capital (ROIC) | -21.64% | -51.85% |
| Return on Tangible Assets | -16.30% | -38.86% |
| Earnings Yield | -2.10% | -3.58% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.85 | 0.59 |
| Payables Turnover | 0.24 | 0.25 |
| Inventory Turnover | 1.87 | 1.73 |
| Fixed Asset Turnover | 0.25 | 0.06 |
| Asset Turnover | 0.16 | 0.05 |
| Working Capital Turnover Ratio | -0.71 | 0.00 |
| Cash Conversion Cycle | -865.87 | -638.81 |
| Days of Sales Outstanding | 429.37 | 618.27 |
| Days of Inventory Outstanding | 195.09 | 210.50 |
| Days of Payables Outstanding | 1490.33 | 1467.58 |
| Operating Cycle | 624.46 | 828.77 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -0.51 | -0.78 |
| Free Cash Flow Per Share | -1.02 | -1.52 |
| Dividend Paid and CapEx Coverage Ratio | -1.00 | -1.05 |
| Capital Expenditure Coverage Ratio | -1.00 | -1.05 |
| Operating Cash Flow Coverage Ratio | -0.23 | -0.73 |
| Operating Cash Flow to Sales Ratio | -0.77 | -5.87 |
| Free Cash Flow Yield | -3.25% | -5.03% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -47.53 | -27.93 |
| Price-to-Sales (P/S) Ratio | 47.37 | 227.42 |
| Price-to-Book (P/B) Ratio | 83.89 | 32.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -30.77 | -19.87 |
| Price-to-Operating Cash Flow Ratio | -61.64 | -38.77 |
| Price-to-Earnings Growth (PEG) Ratio | 1.22 | 0.00 |
| Enterprise Value Multiple | -71.64 | -33.07 |
| Enterprise Value | 13.02B | 12.24B |
| EV to EBITDA | -71.64 | -33.07 |
| EV to Sales | 50.17 | 234.63 |
| EV to Free Cash Flow | -32.59 | -20.50 |
| EV to Operating Cash Flow | -65.28 | -40.00 |
| Tangible Book Value Per Share | 0.31 | 0.86 |
| Shareholders’ Equity Per Share | 0.37 | 0.92 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.00 |
| Revenue Per Share | 0.66 | 0.13 |
| Net Income Per Share | -0.66 | -1.08 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | 1.07 | 1.02 |
| Research & Development to Revenue | 0.79 | 5.43 |
| SG&A to Revenue | 0.47 | 0.37 |
| Stock-Based Compensation to Revenue | 0.16 | 0.92 |
| Income Quality | 0.77 | 0.72 |
Currency in CNY
